Business context and reporting period
Important issuer discrepancy: The supplied filing is for Dynamics Special Purpose Corp., a blank-check company, not Senti Biosciences Holdings, Inc. Investors should verify that this is the intended filing. The unaudited Form 10-Q covers the quarter ended September 30, 2021; the company was incorporated March 1, 2021 and had not commenced operations.
Financial highlights
- Revenue: No operating revenue. Management said revenue is not expected until after a business combination, at the earliest.
- Net loss: $291,680 for the quarter and $498,924 from inception through September 30, 2021. Quarterly loss reflected $253,456 of operating and formation costs and $41,184 of franchise tax expense, partly offset by $2,960 of trust-account interest and dividend income.
- Cash flow: Inception-to-date operating cash use was $1.05 million. Investing cash use was $230.0 million, primarily the trust-account deposit; financing cash provided was $232.0 million. Ending cash outside the trust was $984,544.
- Assets and liquidity: Total assets were $231.7 million, including $230.0 million in the trust account. Working capital was $1.53 million. Management believed available working capital and borrowing capacity would meet needs through the earlier of a business combination or one year from filing.
- Debt and obligations: No debt balance was reported at quarter-end. The $250,000 sponsor promissory note was repaid. An $8.05 million deferred underwriting fee is payable only if a business combination closes. Potential sponsor or insider working-capital loans are discretionary; up to $2.0 million could be convertible at the lender’s option.
- Margins: Not meaningful because the company had no operating revenue.
Changes and unusual items
The company revised previously issued financial statements to classify all 23.0 million public shares as temporary equity, rather than partly in permanent equity, and revised its earnings-per-share allocation. The company said these non-cash corrections did not affect cash, operating expenses, or total cash flows. The filing provides inception-to-date results but no prior-year comparable period.
Outlook, risks and contingencies
- The company’s purpose was to identify and complete a business combination; it had until May 28, 2023 to do so. If unsuccessful, it must cease operations and redeem public shares, subject to the charter and applicable law.
- Management said funds outside the trust would support target identification, due diligence and transaction costs. Additional sponsor/insider loans were possible but not committed.
- COVID-19 could adversely affect the company’s financial position, operations or target search, but the impact was not determinable. The filing states no material changes to prospectus risk factors and reports no legal proceedings.
- The company reported no off-balance-sheet arrangements. Disclosure controls were assessed as effective, with no material quarterly change in internal control over financial reporting.
Most important facts to verify
- Confirm the filing belongs to the intended issuer: the document names Dynamics Special Purpose Corp., not Senti Biosciences Holdings, Inc.
- Verify trust-account balance, redemption terms, and the May 28, 2023 business-combination deadline.
- Review the financial-statement revision and its effect on temporary equity and per-share loss presentation.
- Confirm whether any business-combination transaction or working-capital financing arose after September 30, 2021; this filing reports no subsequent event requiring disclosure.